155 related articles for article (PubMed ID: 32463748)
41. Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital.
Lee R; Beattie M; Crawford B; Mak J; Stewart N; Komaromy M; Esserman L; Shaw L; McLennan J; Strachowski L; Luce J; Ziegler J
Genet Test; 2005; 9(4):306-12. PubMed ID: 16379544
[TBL] [Abstract][Full Text] [Related]
42. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
[TBL] [Abstract][Full Text] [Related]
43. Genetic counselling for hereditary predisposition to ovarian and breast cancer.
Mackay J; Szecsei CM
Ann Oncol; 2010 Oct; 21 Suppl 7():vii334-8. PubMed ID: 20943638
[TBL] [Abstract][Full Text] [Related]
44. An Applied Framework in Support of Shared Decision Making about
Silverman TB; Kuperman GJ; Vanegas A; Sin M; Dimond J; Crew KD; Kukafka R
AMIA Annu Symp Proc; 2018; 2018():961-969. PubMed ID: 30815139
[TBL] [Abstract][Full Text] [Related]
45. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
[TBL] [Abstract][Full Text] [Related]
46. Population-based genetic testing for Women's cancer prevention.
Evans O; Gaba F; Manchanda R
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():139-153. PubMed ID: 32245629
[TBL] [Abstract][Full Text] [Related]
47. Current Status of the Management of Hereditary Breast and Ovarian Cancer in Asia: First Report by the Asian BRCA Consortium.
Nakamura S; Kwong A; Kim SW; Iau P; Patmasiriwat P; Dofitas R; Aryandono T; Hu Z; Huang CS; Ginsburg O; Rashid MU; Sarin R; Teo SH
Public Health Genomics; 2016; 19(1):53-60. PubMed ID: 26575363
[TBL] [Abstract][Full Text] [Related]
48. Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study.
Brédart A; Kop JL; Dick J; Cano A; De Pauw A; Anota A; Brunet J; Devilee P; Stoppa-Lyonnet D; Schmutzler R; Dolbeault S
BMJ Open; 2019 Sep; 9(9):e029926. PubMed ID: 31551380
[TBL] [Abstract][Full Text] [Related]
49. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
50. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
El Ansari FZ; Jouali F; Marchoudi N; Bennani MM; Ghailani NN; Barakat A; Fekkak J
BMC Cancer; 2020 Aug; 20(1):747. PubMed ID: 32778078
[TBL] [Abstract][Full Text] [Related]
51. Patterns of referral and uptake of BReast CAncer (BRCA) gene testing of eligible women with ovarian cancer in New Zealand.
Fraser K; Tan AL; Innes C; Stephens R; Tristram A; Petrich S; Lintott C; Sykes PH; Gamet K; Christian A; Simcock B
N Z Med J; 2019 Feb; 132(1490):26-35. PubMed ID: 30789886
[TBL] [Abstract][Full Text] [Related]
52. Beyond BRCA: A Case Series Examining the Advent of Multigene Panel Testing.
Reap L; Ahsan S; Saleh M
Clin Breast Cancer; 2018 Aug; 18(4):e431-e439. PubMed ID: 29739691
[No Abstract] [Full Text] [Related]
53. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
54. Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the "Angelina Jolie Effect".
Staudigl C; Pfeiler G; Hrauda K; Renz R; Berger A; Lichtenschopf R; Singer CF; Tea MK
BMC Cancer; 2016 Jul; 16():436. PubMed ID: 27391110
[TBL] [Abstract][Full Text] [Related]
55. Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?
Randall TC; Armstrong K
Curr Treat Options Oncol; 2016 Aug; 17(8):39. PubMed ID: 27315065
[TBL] [Abstract][Full Text] [Related]
56. Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Tedaldi G; Tebaldi M; Zampiga V; Danesi R; Arcangeli V; Ravegnani M; Cangini I; Pirini F; Petracci E; Rocca A; Falcini F; Amadori D; Calistri D
Oncotarget; 2017 Jul; 8(29):47064-47075. PubMed ID: 28423363
[TBL] [Abstract][Full Text] [Related]
57. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
[TBL] [Abstract][Full Text] [Related]
58. Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster.
Nippert I; Schlegelberger B;
Community Genet; 2003; 6(4):249-58. PubMed ID: 15331871
[TBL] [Abstract][Full Text] [Related]
59. Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations.
Gambino G; Tancredi M; Falaschi E; Aretini P; Caligo MA
Int J Mol Med; 2015 Apr; 35(4):950-6. PubMed ID: 25683334
[TBL] [Abstract][Full Text] [Related]
60. [Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome].
Foretová L; Macháčková E; Palácová M; Navrátilová M; Svoboda M; Petráková K
Klin Onkol; 2016; 29 Suppl 1():S9-13. PubMed ID: 26691937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
